ZVRA
Q4 2026 EPS Estimate
$0.14
Nov 4, 2026 · Reports after close
Revenue Estimate
$37M
FY2026E EPS$1.11
FY2027E EPS$0.94

Analyst Sentiment

Wall St. Consensus
Buy
10 analysts·Moderate coverage
75
Score
10 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
10100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$20.00
+69.6%
Consensus
$24.00
+103.5%
Bull
$35.00
+196.8%
12-Month Target Range10 analysts
$20.00$24.00$35.00
Current $11.79Consensus
Current Price
$11.79
Upside to Consensus
$12.21

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+16.26%
EPS-15.63%
FY2028
Rev+25.36%
EPS+50.76%
FY2029
Rev+20.17%
EPS+37.24%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$152M$177M$222M$267M$315M
Low$149M$169M$182M$243M$287M
High$156M$183M$261M$291M$344M
EBITDA Avg$-71M$-83M$-104M$-125M$-148M
Low$-73M$-86M$-123M$-137M$-162M
High$-70M$-80M$-86M$-114M$-135M
EBIT Avg$-73M$-85M$-106M$-128M$-151M
Low$-75M$-88M$-125M$-140M$-165M
High$-72M$-81M$-87M$-116M$-137M
Net Income Avg$63M$66M$106M$111M$141M
Low$60M$35M$35M$98M$124M
High$67M$73M$124M$124M$158M
EPS Avg$1.11$0.94$1.41$1.94$2.46
Low$1.05$0.61$0.61$1.71$2.17
High$1.17$1.28$2.17$2.17$2.75
Analysts (Rev / EPS)7 / 57 / 57 / 73 / 25 / 4
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$37M$40M$41M$44M$47M$49M$50M$56M
Low$36M$38M$39M$42M$44M$46M$47M$53M
High$38M$42M$44M$47M$50M$52M$53M$59M
EBITDA Avg$-17M$-19M$-19M$-21M$-22M$-23M$-23M$-26M
Low$-18M$-20M$-21M$-22M$-23M$-24M$-25M$-28M
High$-17M$-18M$-18M$-20M$-21M$-22M$-22M$-25M
EBIT Avg$-18M$-19M$-20M$-21M$-22M$-23M$-24M$-27M
Low$-18M$-20M$-21M$-23M$-24M$-25M$-25M$-28M
High$-17M$-18M$-19M$-20M$-21M$-22M$-23M$-25M
Net Income Avg$10M$11M$15M$17M$18M$19M$17M$21M
Low$8M$9M$14M$16M$16M$18M$16M$20M
High$10M$13M$16M$18M$19M$21M$19M$23M
EPS Avg$0.16$0.18$0.24$0.27$0.29$0.31$0.28$0.34
Low$0.12$0.15$0.22$0.26$0.27$0.29$0.27$0.32
High$0.17$0.20$0.26$0.30$0.31$0.34$0.31$0.37
Analysts (Rev / EPS)6 / 36 / 33 / 13 / 13 / 13 / 14 / 24 / 2

Earnings Surprises

Recent Analyst Actions

Jul 27, 2026Guggenheim
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
Target:$24.00
+152.0%from $9.53
Jul 27, 2026BTIG
Zevra Therapeutics price target lowered to $24 from $27 at BTIG
Target:$24.00
+152.0%from $9.53
Jul 27, 2026Canaccord Genuity
Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $20 at Canaccord
Target:$20.00
+110.0%from $9.53
Jun 10, 2026Maxim Group
Zevra Therapeutics price target raised to $35 from $25 at Maxim
Target:$35.00
+156.1%from $13.67
Jun 10, 2026Guggenheim
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Guggenheim
Target:$29.00
+112.3%from $13.66
Jun 9, 2026Canaccord Genuity
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $29 at Canaccord
Target:$29.00
+139.9%from $12.09
May 8, 2026Guggenheim
Zevra Therapeutics price target raised to $25 from $23 at Guggenheim
Target:$25.00
+127.3%from $11.00
Mar 10, 2026Guggenheim
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $23 at Guggenheim
Target:$23.00
+108.5%from $11.03
Dec 30, 2025H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)
Target:$26.00
+194.8%from $8.82
Nov 6, 2025Cantor Fitzgerald
Zevra Therapeutics price target lowered to $24 from $29 at Cantor Fitzgerald
Target:$24.00
+158.5%from $9.29
Nov 6, 2025Canaccord Genuity
Zevra Therapeutics price target lowered to $24 from $25 at Canaccord
Target:$24.00
+168.2%from $8.95
Mar 13, 2025Guggenheim
Zevra Therapeutics price target raised to $22 from $20 at Guggenheim
Target:$22.00
+177.1%from $7.94
Mar 12, 2025JMP Securities
Zevra Therapeutics price target raised to $18 from $17 at Citizens JMP
Target:$18.00
+127.3%from $7.92
Feb 4, 2025Guggenheim
Zevra Therapeutics price target raised to $21 from $20 at Guggenheim
Target:$21.00
+158.3%from $8.13
Sep 24, 2024Roth Capital
Zevra Therapeutics price target raised to $21 from $19 at Roth MKM
Target:$21.00
+177.0%from $7.58
Sep 24, 2024Maxim Group
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $25 at Maxim Group
Target:$25.00
+229.8%from $7.58
Sep 24, 2024JMP Securities
JMP Securities Starts Zevra Therapeutics, Inc. (ZVRA) at Market Outperform
Target:$17.00
+124.3%from $7.58
Sep 23, 2024H.C. Wainwright
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $20 at H.C. Wainwright
Target:$20.00
+152.5%from $7.92
Sep 18, 2024Canaccord Genuity
Zevra Therapeutics, Inc. (ZVRA) PT Lowered to $22 at Canaccord Genuity
Target:$22.00
+192.2%from $7.53
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.